under-valued outlicens near-term
revenu potenti organ growth promis
assum coverag maintain outperform rate rais
price target view proven platform base busi
outlicens early-clin stage asset under-valued potenti morph
tradit biotechnolog play consid potenti equival
forteo treatment osteoporosi main valu driver set bring substanti
revenu earli remind await fda verdict te-rat
partner alvogen ask addit cuhf data fom forteo-
experienc user may also benefit partner launch
protein carrier pneumoccoc conjuag vaccin
earli
technolog proven
technolog abil produc larg amount natur engin protein
success rate fund compani
partnership also may enabl wholli own asset becom
tradit biotech compani longer term
could repres substanti sourc revenu earli
potenti first-to-market te non-brand altern forteo treat
osteoporosi expect launch could gener us royalti next
year alreadi fda approv product quickli take market
share forteo current repres around commerci
deal attract revenu gener road although
still wait phase data readout pneumoccoc conjug
vaccin suppli carrier protein lead attract
mileston payment royalti us market
despit key catalyst around corner expect hear fda
guidanc cuhf trial design forteo-experienc user addit
anticip phase data readout prevent
pneumoccoc diseas potenti launch siipl pneumosil
final expect interim analysi pivot phase trial
assum outperform lift pt pt base sum-of-the-part
valuat us royalti ou royalti
us royalti ou royalti
royalti cash tech adjust estim account
slightli better market penetr
year price histori
focus develop protein-
base therapi vaccin use
proprietari platform
program consist potenti
therapeut equival te forteo
treatment osteoporosi well
recombin crisantaspas
patient hypersensit coli
analyst certif import disclosur see disclosur
interest blend near-
believ offer
term signific revenue-gener royalti meaning
partnership long-term potenti organ growth
wholli own asset clinic valid proprietari
technolog platform expect partner launch earli
osteoporosi hematolog
infectious-diseas vaccin outperform rate
base view main valu driver may launch
address us market opportun approxim
registration-en data two
partnership could gener signific upsid level
demonstr therapeut equival te launch
achiev sale provid royalti stream
gross profit
launch provid royalti
stream net sale
approv launch provid
royalti stream net sale
fda guidanc cuhf trial design
phase studi data prevent
pneumococc diseas
siipl launch pneumosil
pivot phase interim analysi
te fda verdict us launch
greater anticip sale
pipelin growth addit partnership
trajectori and/or
demonstr te
launch delay past
failur achiev approv lower royalti
valu us base multipl royalti estim royalti discount year fda
te decis pend valu ou base multipl discount rate forecast royalti
valu us royalti base expect royalti discount year pre-data
erwinaz alreadi commerci valu ou base multipl discount rate estim
royalti valu base expect royalti discount pre-data
strong competit mileston cash tech valu
obtain therapeut equival gener forteo competitor enter us market earlier failur achiev approv
licens servic revenu
revenu cog
inc loss op
incom net
inc loss tax
ni report
ep report
compani report oppenheim estim
stock price compani mention report
